Aradigm increases SmartMist production:
This article was originally published in Clinica
Executive Summary
Aradigm is scaling-up production of its SmartMist drug delivery system for a 1997 launch following 510(k) clearance by the US FDA. Phase I clinical trials for the inhalation delivery of morphine using the company's AERx system are under way and the company is conducting clinical feasibility studies for insulin delivery and diagnostic pulmonary imaging. The Californian company raised $24.7 million in its IPO in June (see Clinica No 713, p 15). Aradigm's six-month net losses were $3.7 million against revenues of $172,500.